Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
Fig 7
Drug concentrations yielding maximum synergy.
Synergy as a function of the concentrations of bryostatin-1 and (A) VPA, (B) NaBut, and (C) TSA, obtained by mapping ϕPKCa and ϕHDACi in Fig 6B to drug concentrations using the dose-response curves in Figs 3 and 4. The maximum synergy attainable is indicated.